4-(1-phenylpiperazin-4-yl)cyclohexylamine | 849411-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(1-phenylpiperazin-4-yl)cyclohexylamine
• 英文别名: Cyclohexanamine, 4-(4-phenyl-1-piperazinyl)-, cis-；4-(4-phenylpiperazin-1-yl)cyclohexan-1-amine
• CAS: 849411-58-1
• 化学式: C₁₆H₂₅N₃
• 分子量: 259.395
• InChiKey: MRHJLNHIRRALBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-phenylpiperazin-4-yl)cyclohexylamine 在 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 氯仿 、 水 为溶剂， 反应 9.0h， 生成 trans-1-[4-(4-phenylpiperazin-1-yl)cyclohexyl]pyrrolidin-2-one
  参考文献：
  名称：

  1-酰亚胺/酰胺基取代的4-（4-芳基哌嗪-1-基）环己烷衍生物的结构-本征活性关系研究；具有抗焦虑活性的新型有效5-HT1A受体药物。

  摘要：

  在柔性长链芳基哌嗪的结构中引入1,4-二取代的环己烷环导致线性约束的有效5-羟色胺（5-HT）（1A）配体。为了追踪该组中的结构-本征活性关系，合成了具有不同环酰亚胺/酰胺末端的一系列新的1-取代的4-（4-芳基哌嗪-1-基）环己烷衍生物，以及它们的柔性四亚甲基类似物，并药理学评估的5-HT（1A）受体。体外结合实验表明，所有化合物均为有效的5-HT（1A）受体试剂（K（i）= 1.9-74 nM）。另外测试的某些衍生物还显示出对α（1）-肾上腺素能受体（K（i）= 2.9-101 nM）和5-HT（7）受体的高亲和力。体内功能检查发现，刚性配体的o-OCH（3）基团在芳基部分和对端末端的环状酰亚胺系统表现得像突触后5-HT（1A）受体拮抗剂。另一方面，未取代的，m-Cl或m-CF（3）取代的衍生物以及在末端片段中具有环状酰胺基的衍生物表现出激动或部分激动活性。测试的四种衍生物中的三种，即

  DOI：

  10.1016/j.bmc.2005.09.060
• 作为产物：
  描述：

  4-(1-phenylpiperazin-4-yl)cyclohexanone oxime 在 sodium 作用下， 以 正丁醇 为溶剂， 以65%的产率得到4-(1-phenylpiperazin-4-yl)cyclohexylamine
  参考文献：
  名称：

  1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), α1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics

  摘要：

  Starting with the structure of potent 5-HT1A ligands, that is, MM77 [1-(2-methoxyphenyl)-4-(4-succinimidobutyl)piperazine, 4] and its constrained version 5 (MP349), previously obtained in our laboratory, a series of their direct analogues with differently substituted aromatic ring (R = H, m-Cl, m-CF3, m-OCH3, p-OCH3) were synthesized. The flexible and the corresponding 1e,4e-disubstituted cyclohexane derivatives were designed in order to investigate the influence of rigidification on 5-HT1A affinity, selectivity for 5-HT2A, 5-HT7, D-1, and D-2 binding sites and functional profile at pre- and postsynaptic 5-HT1A receptors. The new compounds 19-25 were found to be highly active 5-HT1A receptor ligands (K-i = 4-44 nM) whereas their affinity for other receptors was: either significantly decreased after rigidification (5-HT7) or controlled by substituents in the aromatic ring (alpha(1)), or influenced by both those structural modifications (5-HT2A), or very low (D-2, K-i = 5.3-31 mu M). Since a distinct disfavor towards rigid compounds was observed for 5-HT7 receptors only, it seems that the bioactive conformation of chain derivatives at those sites should differ from the extended one.Several in vivo models were used to asses functional activity of 19-25 at pre- (hypothermia in mice) and postsynaptic 5-HT1A receptors (lower lip retraction in rats and serotonin syndrome in reserpinized rats). Unlike the parent antagonists 4 and 5, all the new derivatives tested were classified as partial agonists with different potency, however, similar effects were observed within pairs (flexible and rigid) of the analogues. The obtained results indicated that substitution in the aromatic ring, but not spacer rigidification, controls the 5-HT1A functional activity of the investigated compounds. Moreover, an o-methoxy substituent in the structure of 5 seems to be necessary for its full antagonistic properties. Of all the new compounds studied, trans-4-(4-succinimidocyclohexyl)-1-(3-trifluoromethylphenyl)piperazine 24 was the most potent 5-HT1A receptor ligand in vitro (Ki = 4 nM) and in vivo, with at least 100-fold selectivity for the other receptors tested. (c) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.12.041

文献信息

• [DE] PI3-KINASEN<br/>[EN] PI3 KINASES<br/>[FR] PI3-KINASES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006040279A1

  公开（公告）日：2006-04-20

  Es werden neue Verbindungen der Formel (1) bereitgestellt, die aufgrund ihrer pharmazeutischen Wirksamkeit als PI3-Kinase Modulator zur Anwendung auf therapeutischem Gebiet zur Behandlung von entzündlichen oder allergischen Erkrankungen gelangen können. Beispielhaft seien hier entzündliche und allergische Atemwegserkrankungen, entzündliche Erkrankungen des Magen-Darm-Traktes und des Bewegungsapparates, entzündliche und allergische Hauterkrankungen, entzündliche Augenerkrankungen, Erkrankungen der Nasenschleimhaut, entzündliche oder allergische Krankheitszustände, bei denen Autoimmun-Reaktionen beteiligt sind oder Nierenentzündungen genannt.

  提供公式（1）的新颖化合物，由于其药理活性可作为PI3激酶调节剂应用于治疗领域，用于治疗炎性疾病或过敏性疾病。例如，这里可以列举的包括炎性和过敏性呼吸道疾病、炎性疾病、胃肠道的运动系统、炎性和过敏性皮肤病、炎性疾病、鼻粘膜疾病、炎症或过敏性疾病，其中涉及自身免疫反应或肾盂肾炎。
• [EN] COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION<br/>[FR] COMBINAISONS POUR TRAITEMENT DE MALADIES IMPLIQUANT UNE PROLIFÉRATION CELLULAIRE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006018182A1

  公开（公告）日：2006-02-23

  The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

  本发明涉及一种用于治疗涉及细胞增殖的疾病的药物组合物。该发明还涉及一种治疗上述疾病的方法，包括共同给药于一种具有以下式(I)的化合物1，其中基团L、R1、R2、R3、R4和R5具有索赔和规范中给定的含义，可选地以其互变异构体、消旋体、对映体、二对映异构体和它们的混合物的形式，以及可选地以药理学上可接受的酸盐、溶剂化合物、水合物、多型、生理功能衍生物或其前药的形式，以及与有效量的活性化合物2和/或辐射治疗共同治疗，其比例提供加成和协同作用，并且结合使用具有以下式(I)的化合物1和有效量的活性化合物2和/或放射治疗用于制备相应的药物组合制剂。
• New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH Co. KG

  公开号：US20040176380A1

  公开（公告）日：2004-09-09

  The present invention relates to new dihydropteridinones of general formula (I) 1 wherein the groups L and R 1 - R 5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

  本发明涉及一般式（I）1的新二氢叶酸酮，其中基团L和R1-R5具有索赔和规范中给出的含义，其异构体，制备这些二氢叶酸酮的过程以及其作为药物组合物的用途。
• [DE] DIHYDROPTERIDINONE, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS<br/>[FR] DIHYDROPTERIDINONES, PRODEDE DE PRODUCTION ET UTILISATION DE CES DERNIERES COMME MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004076454A1

  公开（公告）日：2004-09-10

  Die vorliegende Erfindung betrifft neue Dihydropteridinone der allgemeinen Formel (I), wobei die Reste L, R1-R5 die in den Ansprüchen und der Beschreibung genannten Bedeutungen haben, deren Isomere, Verfahren zur Herstellung dieser Dihydropteridinone sowie deren Verwendung als Arzneimittel.

  本发明涉及一种新的一氢叶酸二氢吡啶酮，其通式为(I)，其中残基L，R1-R5具有权利要求和说明中提到的含义，其异构体，制备这些一氢叶酸二氢吡啶酮的方法以及它们作为药物的用途。
• Storage stable perfusion solution for dihydropteridinones
  申请人：Mohr Detlef

  公开号：US20060035903A1

  公开（公告）日：2006-02-16

  Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

  公开了含有一种一般式（I）的活性物质的储存稳定的水性不可注射或可注射溶液，其中组L、R1、R2、R3、R4和R5具有声明中给出的含义和说明书中的含义，以及足以溶解活性物质并起稳定剂作用的生理可接受酸或酸混合物的量，可选地与适用于肌肉注射的其他配方辅料一起，并根据本发明制备不可注射或可注射溶液的方法。